The Chinese company InnoCare Pharma announced today (12/28) that its BTK inhibitor orelabrutinib received approval for the treatment of cancer and autoimmune diseases, specifically relapsed/refractory chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL), a malignant tumor that effects 93,000 annually. China’s approval of InnoCare’s inhibitor brings the pharmaceutical company from clinical to commercial status, joining the numerous other commercial pharma giants in the dense Chinese market for innovative and cutting edge technology.
Learn more here.
More on: News Regulatory